SOUTHWEST ONCOLOGY GROUP

描述（改编自申请人摘要）：韦恩州立大学 (WSU)一直是西南肿瘤学的活跃机构成员 集团超过25年，招募超过4500名患者进入临床试验。 这些年来，他们的教师在支持 SWOG，通过在行政和科学职能方面提供领导 的SWOG，并通过满足和超越患者的累积目标， 持续和一致的方式。 因此，WSU一直保持在第一位 SWOG在每个国家进行的机构绩效评估的四分位数 过去五年里 华盛顿州立大学的癌症临床研究项目 沿着多学科疾病导向研究的路线组织 并以类似于SWOG的器官委员会取向的方式。 因此，他们的教师在科学SWOG委员会的代表是 由具有这些领域的专门知识和承诺的个人组成 的研究。 因此，将思想转化为SWOG研究， 以及将SWOG研究和NCI指定的高 优先试验纳入WSU治疗优先事项，很容易促进。 在 此外，他们所在地区的人口结构和承诺， 研究人员向所有患者提供临床试验，显然是 在招募少数民族（33%）和妇女（46%）时， %）进入SWOG临床试验。 SWOG在WSU的成员资格和 他们的教师参与学科的多样性继续增长 多年来 迄今为止，87名WSU成员目前在38个国家任职， 委员会。 同样，60项SWOG研究将WSU成员列为研究 主席或作为研究协调员，因为最后一个竞争的应用程序是 已提交。 Lawrence Flaherty博士，自1986年以来一直是SWOG成员， SWOG黑色素瘤委员会副主席，成为校长 在Manuel博士离开时， Valdivieso为另一个机构。 他将保持WSU的突出地位 作为SWOG成员机构。

Description (Adapted from the applicant's abstract): Wayne State University (WSU) has been an active institutional member of the Southwest Oncology Group for over 25 years, enrolling over 4500 patients onto clinical trials. Over these years, their faculty have played an important role in support of SWOG, by providing leadership in the administrative and scientific functions of SWOG, and also by meeting and exceeding patient accrual goals in a continuous and consistent manner. Thus, WSU has remained in the first quartile of institution's performance evaluation conducted by SWOG in each of the last five years. The clinical research program in cancer at WSU has been organized along the lines of multidisciplinary disease oriented studies and in a manner which resembles the organ committee orientation of SWOG. Thus, their faculty's representation in scientific SWOG committees is constituted by individuals with expertise and commitment towards those areas of research. Accordingly, the translation of ideas into SWOG studies as well as the incorporation of SWOG studies and those of NCI designated high priority trials into WSU treatment priorities, are easily facilitated. In addition, the demographics of their region and the commitment of investigators to make clinical trials available to all patients, is clearly identified in their recruitment of minorities (33 percent) and women (46 percent) into SWOG clinical trials. The SWOG membership in WSU and the diversity of disciplinary involvement by their faculty has continued to grow over the years. To date, 87 WSU members are currently serving on 38 committees. Similarly, 60 SWOG studies list a WSU member as a study chairman or as study coordinator since the last competing application was submitted. Dr. Lawrence Flaherty, a SWOG member since 1986 and Vice-Chairman of the SWOG Melanoma Committee, becomes the Principal Investigator of this competing renewal at the departure of Dr. Manuel Valdivieso for another institution. He will maintain the prominence of WSU as a SWOG member institution.